Xenon Pharmaceuticals Inc.

Genentech, Inc.

Pfizer Corporation

Wyeth

Wyeth Holdings Corporation

Christoph Martin Dehnhardt

Sultan Chowdhury

Thilo Focken

Michael Edward Grimwood

Alla Yurevna Zenova

Ivan William Hemeon

Shaoyi Sun

Brian Salvatore Safina

Qi Jia

Kevin Joseph Curran

Jean-Christophe Andrez

Michael Scott Wilson

Daniel P Sutherlin

Joseph Walter Strohbach

Kristen Nicole Burford

Aranapakam Mudumbai Venkatesan

Ariamala Gopalsamy

Arie Zask

Eddine Saiah

David James Richard

Tarek Suhayl Mansour

David Hepworth

Christoph Wolfgang Zapf

Efren Guillermo Delos Santos

Arthur Lee

Nikolaos Papaioannou

Stephen Wayne Wright

Frank Eldridge Lovering

Katherine Lin Lee

John David Trzupek

Jeroen Cunera Verheijen

Joshua Aaron Kaplan

Mengxiao Shi

Zecheng Chen

Osvaldo Dos Santos

Seungil Han

Lori Krim Gavrin

Semiramis Ayral-Kaloustian

John Paul Mathias

Paul Robert Bichler

Daniel Fred Ortwine

Akshay Patny

Xiaolun Wang

Joel A Goldberg

Michael Dennis Lowe

Richard Vargas

Abid Hasan

Shannon Marie Decker

David R Anderson

Mark Edward Bunnage

Panolil C Raveendranath

Horng-Chih Huang

Ronald Stanley Michalak

Philippe Bergeron

Betsy Susan Pierce

Wei Gong

Syed Abid Hasan

Tao Sheng

Peter M Jones

Jotham Wadsworth Coe

Gavin Alistair Whitlock

Robert Joseph Devita

Jun M Li

Steven McKerrall

Florian Michel Wakenhut

Zhiguo Liu

James Philip Johnson, Jr

James Roy Empfield

Charles Jay Cohen

Sreenivasulu Megati

Steven Sigmund Wesolowski

Michael William Winkley

Mousumi Ghosh

Jiuxiang Zhu

Verner Alexander Lofstrand

Mahmut Levent

Charles Guinosso

Frederick J Vyverberg

Ara R Boyajian

Michel Cantin

Alan Stockton

Andrew D White

Dafydd Rhys Owen

Yogesh Anil Sabnis

Yogesh Sabnis

Christophe Philippe Allais

Chien-An Chen

Chien-an Chen

Tao Wang

David Earl Bogucki

Kwong Wah Lai

Jianxin Ren

Charles Chao Wu

Jerry Sun

Joel Adam Goldberg

Semiramis Aryl-Kaloustian

Steven Wade Korturn

Steven Wade Kortum

Yangzhong Wu

Dan Sutherlin

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. In an embodiment, a pharmaceutical composition can be in a liquid dosage form and can comprise a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof as an adjuvant and a therapeutic agent. In another embodiment, a method of adjuvant treating a disorder or condition can comprising administering the pharmaceutical composition to a patient.

Bicyclic-fused heteroaryl or aryl compounds

Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents

This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

Benzenesulfonamide compounds and their use as therapeutic agents

The invention provides compounds having the general formula I: and pharmaceutically acceptable salts thereof, wherein the variables R, R, subscript n, ring A, X, L, subscript m, X, ring B, R, and Rhave the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

Substituted benzamides and methods of use thereof

Benzenesulfonamide compouds and their use as therapeutic agents

The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables R, R, subscript n, subscript q, ring A, X, L, subscript m, X, R, R, R, R, R, D and E have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

Therapeutic compounds and methods of use thereof

The invention provides compounds having the general formula (I): and pharmaceutically acceptable salts thereof, wherein the variables R, R, n, ring A, X, L, m, R, R, R, R, R, and Rhave the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions. 

Substituted benzamides useful as sodium channel blockers

The invention provides a compound of formula: or a salt thereof, wherein the variables R, n, ring A, ring B, R, R, R, R, R, R, R, R, R, and Rhave the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

The invention provides compounds having the general formula I: (i) and pharmaceutically acceptable salts thereof, wherein the variables R, R, subscript n, ring A, X, L, subscript m, X, ring B, R, and Rhave the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions. 

This invention is directed to heteroaryl-substituted sulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors

This invention is directed to methods of preparing benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

Growing community of inventors

Burnaby, Canada

Christoph Martin Dehnhardt